Compiled report on clinical efficacy and safety of nifedipine retard 10/20/nifedipine CD 30, as a first-line/add-on therapy in patients of hypertension: ENHANS trial.
The effectiveness of long acting nifedipine (Nicardia retard 10/20/30 CD) was evaluated on Indian patients in multiple centres. This was an open, prospective, clinical multicentric trial. Nearly 1632 patients satisfying the inclusion criteria were selected and given long acting nifedipine and assessed regularly for a period of one month. The reduction in the arterial blood pressure was significant from the 3rd day onwards and the target systolic and diastolic blood pressures were reached by the 14th day and the 7th day respectively, without notable changes in other parameters. At the final visit 18.6% and 16.1% reduction from the baseline was witnessed in the systolic and diastolic blood pressures respectively; 67.3% and 76% of individual patients had achieved target systolic and diastolic pressures respectively at end of one month. The heart rate was also found to be significantly reduced in the course of the trial (2.1% from the baseline). No other physical and investigational parameters were affected. Moreover 56.3% and 55.8% patients and physicians respectively rated the treatment as "very good" or "excellent" at the end of the study period. Thus, from this trial it is clear that long acting nifedipine is very efficacious as a first-line drug in the armamentarium against hypertension, while controlling other modifiable risk factors for cardiovascular disease.